Skip to main content
. Author manuscript; available in PMC: 2017 Dec 1.
Published in final edited form as: Epidemiol Methods. 2016 Jan 23;5(1):93–112. doi: 10.1515/em-2015-0007

Table 3.

Estimated VE*(t = 39) × 100% in the New Setting (HVTN 702) Under Different Estimation and Modeling Approaches1

S(1*) Distribution ACN Assump.
VE^(t=39)×100%
Est. (95% CI) γ = 1 Ign. int.2 95% EUI1
Same as RV144 (Fig. 3A) for X = 0 34.6 (11.1, 65.8) (27.7, 43.3) (8.9, 82.2)
Higher3 for X* = 0 (Fig. 3B) for X = 0 36.1 (11.0, 65.9) (28.9, 45.2) (8.8, 82.4)
Higher3 for X* = 1 (Fig. 3C) for X = 0 36.6 (11.0, 65.9) (29.3, 45.7) (8.8, 82.4)
Higher3 for All (Fig. 3D) for X = 0 38.1 (10.6, 67.0) (30.5, 47.6) (8.5, 83.7)
Same as RV144 (Fig. 4A) for X = 1 38.0 (14.0, 67.2) (30.4, 47.5) (10.9, 84.1)
Higher3 for X* = 0 (Fig. 4B) for X = 1 42.7 (14.0, 68.5) (34.2, 53.4) (11.2, 85.7)
Higher3 for X* = 1 (Fig. 4C) for X = 1 39.2 (14.0, 68.5) (31.3, 49.0) (11.2, 85.7)
Higher3 for All (Fig. 4D) for X = 1 43.9 (16.5, 75.5) (35.1, 54.9) (13.2, 94.3)
Higher4 for All for X = 0 40.7 (6.7, 74.2) (31.8, 50.9) (2.6, 93.4)
Higher4 for All for X = 1 55.8 (23.2, 94.0) (44.8, 70.1) (19.3, 100)
Model Adding a v = 1 Strain Assuming VE^(t=39,v=1s1,x)=VE^(t=39,v=0s1,x)
Higher3 for All for X = 0 52.3 (15.1, 92.7) (41.8, 65.3) (12.0, 100)
Higher3 for All for X = 1 60.3 (23.6, 100) (48.2, 75.4) (18.8, 100)
Higher4 for All for X = 0 55.8 (6.3, 100) (44.1, 69.6) (0.0, 100)
Higher4 for All for X = 1 76.7 (33.3, 100) (61.5, 96.3) (26.9, 100)
1

The estimation is done as described in Table 2, except for new elements listed in this table.

2

Computed for ϕ(t, v|s1, x) = γ with γ ranging over [ 1Γ Γ] for Γ = 1.25, where ϕ(t, v|s1, x) ≡ VE*(t = 39, v|s1, x)/VE(t = 39, v|s1, x).

3

Estimation scenario of equal support of (X*, S(1*)) and (X, S(1)), where the distribution of S(1*) follows a modification of *(s1|x) from RV144 data (Figure 2) by moving a random sample of 75% of the original Si(1) values with percentile p ≤ 0.50 in RV144 to the percentile p* = p + 0.50.

4

Estimation scenario of equal support of (X*, S(1*)) and (X, S(1)), where the distribution of S(1*) is uniformly distributed in the highest range of immune responses supported by the binding assay, [9, 10.1].